GB995338A - Polysaccharides and methods for their production - Google Patents

Polysaccharides and methods for their production

Info

Publication number
GB995338A
GB995338A GB3719263A GB3719263A GB995338A GB 995338 A GB995338 A GB 995338A GB 3719263 A GB3719263 A GB 3719263A GB 3719263 A GB3719263 A GB 3719263A GB 995338 A GB995338 A GB 995338A
Authority
GB
United Kingdom
Prior art keywords
polysaccharide
aqueous solution
acid
staphylococcus aureus
chloroacetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3719263A
Inventor
Henry Blessing Devlin
Theodore Herbert Haskell
Myron Wolf Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parke Davis and Co LLC
Original Assignee
Parke Davis and Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parke Davis and Co LLC filed Critical Parke Davis and Co LLC
Priority to GB3719263A priority Critical patent/GB995338A/en
Publication of GB995338A publication Critical patent/GB995338A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates

Abstract

In a process for the production of a staphylococcal antigen product, intact cells of a strain of Staphylococcus aureus identifiable by the property of forming loosely-cohesive, diffuse, semi-opaque colonies when grown in a semi-solid or soft agar culture medium containing plasma, serum or protein components thereof, are reacted with an aqueous acid at a pH of not more than 4 and the resulting aqueous solution containing an immunogenic polysaccharide is separated from insoluble solid material, the aqueous solution, upon adjustment to a pH acceptable for injection, being capable of stimulating the formation of a protective anti-body against Staphylococcus aureus. Specified Staphyloccus aureus strains are UC76, Smith, S193N4, H & D, Castellani, MCD138, SK4473, K6, K93 and K93M. The intact cells may be live or "killed" by e.g. heat-treatment, or treatment with phenol or b -propiolactone. The acid reactant may be e.g. aqueous acetic, formic, propionic, mono-chloroacetic, tri-chloroacetic or hydrochloric acids. The aqueous solution of polysaccharide, after separation from solids, may be used as a vaccine, the pH being adjusted to one suitable for parenteral injection, e.g. pH 6-8. The vaccine may be made isotonic by addition of sodium chloride and sterilized by heat, ultra-violet irradiation, or by addition of a preservative such as phenol, thimerosol or benzethonium chloride. Alternatively, the polysaccharide may be isolated from its aqueous solution by e.g. dialysis and freeze-drying, and may be purified by e.g. chromatography, precipitation of impurities, or by formation of a quaternary ammonium complex. The polysaccharide contains carboxyl groups and may be obtained as free acid, or in the form of sodium, potassium, calcium, magnesium, ammonium or amine salts. In examples, cultures of the UC76 strain of Staphylococcus aureus are treated with 0.1N acetic acid at 100 DEG C., 1N and 0.1N acetic acid at 121 DEG C. and tri-chloroacetic acid at room temperature. The extracted polysaccharide resembles in properties polysaccharide II disclosed in the parent Specification.ALSO:In a process for the production of a staphylococcal antigen product, intact cells of a strain of staphylococcus aureus identifiable by the property of forming loosely-cohesive, diffuse, semi-opaque colonies when grown in a semi-solid or soft agar culture medium containing plasma, serum or protein components thereof, are reacted with an aqueous acid at a pH of not more than 4 and the resulting aqueous solution containing an immunogenic polysaccharide is separated from insoluble solid material, the aqueous solution, upon adjustment to a pH acceptable for injection, being capable of stimulating the formation of a protective antibody against staphylococcus aureus. Specified staphylococcus aureus strains are UC76, Smith, S 193N4, H & D, Castellani, MCD138, SK4473, K6, K93 and K93M. The intact cells may be live or "killed" by e.g. heat-treatment, or treatment with phenol or b -propiolactone. The acid reactant may be, e.g., aqueous acetic, formic, propionic, monochloroacetic, tri-chloroacetic or hydrochloric acids. The aqueous solution of polysaccharide, after separation from solids, may be used as a vaccine, the pH being adjusted to one suitable for parenteral injection, e.g. pH 6-8. The vaccine may be made isotonic by addition of sodium chloride and sterilized by heat, ultra-violet irradiation, or by addition of a preservative such as phenol, thimerosol or benzethonium chloride. Alternatively, the polysaccharide may be isolated from its aqueous solution by, e.g. dialysis and freeze-drying, and may be purified by, e.g. chromatography, precipitation of impurities, or by formation of a quaternary ammonium complex. The polysaccharide contains carboxyl groups and may be obtained as free acid, or in the form of sodium, potassium, calcium, magnesium, ammonium or amine salts. In examples, cultures of the UC76 strain of staphylococcus aureus are treated with 0,1N acetic acid at 100 DEG C., IN and 0,1N acetic acid at 121 DEG C., and tri-chloroacetic acid at room temperature. The extracted polysaccharide resembles in properties polysaccharide II disclosed in the parent Specification.
GB3719263A 1963-09-20 1963-09-20 Polysaccharides and methods for their production Expired GB995338A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB3719263A GB995338A (en) 1963-09-20 1963-09-20 Polysaccharides and methods for their production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3719263A GB995338A (en) 1963-09-20 1963-09-20 Polysaccharides and methods for their production

Publications (1)

Publication Number Publication Date
GB995338A true GB995338A (en) 1965-06-16

Family

ID=10394531

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3719263A Expired GB995338A (en) 1963-09-20 1963-09-20 Polysaccharides and methods for their production

Country Status (1)

Country Link
GB (1) GB995338A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2468372A1 (en) * 1977-09-30 1981-05-08 Yoshida Kosaku NEW VACCINE AGAINST INFECTIOUS DISEASES IN BOVINE AND METHOD OF PRODUCING THE SAME
US20120282295A1 (en) * 2009-10-30 2012-11-08 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2468372A1 (en) * 1977-09-30 1981-05-08 Yoshida Kosaku NEW VACCINE AGAINST INFECTIOUS DISEASES IN BOVINE AND METHOD OF PRODUCING THE SAME
US20120282295A1 (en) * 2009-10-30 2012-11-08 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
US9060965B2 (en) * 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
US9441004B2 (en) 2009-10-30 2016-09-13 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 8 capsular saccharides
EP2493498B1 (en) 2009-10-30 2017-03-22 GlaxoSmithKline Biologicals SA Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
US11208424B2 (en) 2009-10-30 2021-12-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus type 5 capsular saccharides

Similar Documents

Publication Publication Date Title
US3396081A (en) Hyaluronic acid preparation and method of producing same
FI79024C (en) Process for the preparation of Haemophilus influenzae b-polysaccharide xotoxoid conjugate vaccine.
US4460575A (en) Vaccinal complex containing a specific antigen and vaccine containing it
EP0530173B1 (en) Method for inactivating prions
GB1473541A (en) Vaccines processes for preparing the same applications thereof and hyperimmune sera prepared therefrom
Walker A method for the isolation of toxic and immunizing fractions from bacteria of the Salmonella group
Lambden et al. Synthesis of immunogenic oligosaccharide-protein conjugates from the lipopolyasaccharide of Neisseria Gonorrhoeae P9
GB995338A (en) Polysaccharides and methods for their production
US3936351A (en) Method for preparing glucoronyl-glucosamino-glycan sulphates exhibiting antilipasaemic activity
DE1617397C3 (en) Production of a tumor static agent by growing Streptococcus haemolyticus
GB979275A (en) A method of preparing polypeptide substance having antiphlogistic properties
US2787576A (en) Attenuating b. abortus and p. multocida
CH423095A (en) Process for the manufacture of a rabies vaccine
EP0298991B1 (en) Novel lectins derived from bacterial pili
US4110434A (en) Novel immunological adjuvants, process for their production and compositions containing them
US3185624A (en) Preparation of purified lipid a from crude lipid a derived from lipopolysaccharides of gram-negative bacteria
Pillemer et al. Separation and immunologic evaluation of soluble pertussal antigens
JPS58129001A (en) Novel immunoligically active polyglucide and its preparation
Kanazawa et al. Pure culture of the pathogenic agent of Tyzzer's disease of mice
US3627642A (en) Lysozyme salts
GB1060513A (en) Process for the preparation of glucuronoglycosaminoglycan hyaluronate lyase
IL29925A (en) Tetanus vaccine and process for preparing it
Kawakami et al. EXPERIMENTAL SALMONELLOSIS III: New Toxic Fraction (L) Obtained from Salmonella enteritidis and Its Immunological Properties
Kanamaru et al. Production of acid heteropolysaccharides from n-paraffine
FI60576B (en) FOERFARANDE FOER FRAMSTAELLNING AV LYSOZYM